12:00 AM
May 28, 2012
 |  BC Week In Review  |  Clinical News  |  Clinical Results

Vedolizumab: Additional Phase III data

Additional data from the double-blind, international Phase III GEMINI I trial showed that 47.1% of patients receiving vedolizumab in the blinded induction cohort (n=225) had a clinical response at week 6, a co-primary endpoint, vs. 25.5% for placebo (n=149; p<0.0001). Additionally, 44.8% and 41.8% of patients who responded to vedolizumab at week 6 (in either the blinded or open-label induction cohorts) and subsequently received vedolizumab every 4 (n=125) and 8 weeks (n=122), respectively, during the maintenance stage of the trial achieved clinical remission at week 52, also a co-primary endpoint, vs. 15.9% for placebo (n=126; p<0.0001 for both).

The trial enrolled 895...

Read the full 495 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >